Prexasertib: an investigational checkpoint kinase inhibitor for the treatment of high-grade serous ovarian cancer
| Autor: | Sara Stigliani, Giulio Evangelisti, Simone Ferrero, Melita Moioli, Claudio Gustavino, Sergio Costantini, Fabio Barra, Paolo Sala |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
endocrine system diseases medicine.medical_treatment Cystadenocarcinoma Checkpoint kinase 1 checkpoint kinase 2 CHK inhibitors high-grade serous ovarian cancer homologous recombination LY2606368 olaparib PARP inhibitors prexasertib Antineoplastic Combined Chemotherapy Protocols Cystadenocarcinoma Serous Drug Synergism Female Humans Neoplasm Grading Ovarian Neoplasms Protein Kinase Inhibitors Pyrazines Pyrazoles Olaparib 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Serous ovarian cancer Medicine Pharmacology (medical) CHEK1 Checkpoint Kinase 2 Pharmacology Chemotherapy Kinase business.industry Serous General Medicine female genital diseases and pregnancy complications Prexasertib 030104 developmental biology chemistry 030220 oncology & carcinogenesis Cancer research Homologous recombination business |
| Zdroj: | Expert opinion on investigational drugs. 29(8) |
| ISSN: | 1744-7658 |
| Popis: | Introduction Patients with high-grade serous ovarian cancer (HGSOC) have a poor prognosis, and current chemotherapy regimens for treating advanced disease are far from satisfactory. Prexasertib (LY2606368) is a novel checkpoint kinase inhibitor (CHK) under investigation for the treatment of HGSOC. Data from a recent phase II trial showed promising efficacy and safety results for treating wild-type BRCA HGSOC. Areas covered This article reviews the available data on the pharmacokinetics, pharmacodynamics, clinical efficacy, and safety of prexasertib in the treatment of HGSOC. Expert opinion Until now, prexasertib demonstrated clinical activity in phase I and II clinical trial for treating wild-type BRCA HGSOC, whereas its promising efficacy as monotherapy and combined with olaparib in BRCA-mutated HGSOC has been preliminary evidenced only in phase I studies. Compared to other drugs of the same class, prexasertib showed a better tolerability profile, causing moderate hematological toxicity. Further studies are needed to confirm efficacy and safety profiles of prexasertib in combined regimens. New early clinical trials may investigate prexasertib administered with programmed cell death ligand 1 (PD-L1) and PI3 K inhibitors due to the preclinical evidence of a synergic action. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|